Gain Therapeutics (GANX) Gains from Sales and Divestitures (2023 - 2025)
Gain Therapeutics has reported Gains from Sales and Divestitures over the past 3 years, most recently at $97952.0 for Q3 2025.
- Quarterly results put Gains from Sales and Divestitures at $97952.0 for Q3 2025, up 58.51% from a year ago — trailing twelve months through Sep 2025 was $97952.0 (up 58.51% YoY), and the annual figure for FY2024 was $61794.0, down 64.02%.
- Gains from Sales and Divestitures for Q3 2025 was $97952.0 at Gain Therapeutics, up from $95069.0 in the prior quarter.
- Over the last five years, Gains from Sales and Divestitures for GANX hit a ceiling of $171751.0 in Q4 2023 and a floor of $31125.0 in Q1 2024.
- Median Gains from Sales and Divestitures over the past 3 years was $65629.5 (2023), compared with a mean of $84608.9.
- Biggest five-year swings in Gains from Sales and Divestitures: plummeted 64.02% in 2024 and later skyrocketed 164.21% in 2025.
- Gain Therapeutics' Gains from Sales and Divestitures stood at $171751.0 in 2023, then plummeted by 64.02% to $61794.0 in 2024, then soared by 58.51% to $97952.0 in 2025.
- The last three reported values for Gains from Sales and Divestitures were $97952.0 (Q3 2025), $95069.0 (Q2 2025), and $63859.0 (Q1 2025) per Business Quant data.